Business Context and Reporting Period
Company: STAAR Surgical Company
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: April 4, 1997
Business Overview: The Company manufactures and sells ophthalmic surgical products, primarily foldable intraocular lenses (IOLs), with significant international operations. Key markets include Europe, South Africa, Australia, and Southeast Asia.
Key Financial Metrics
| Metric | Q1 1997 | Q1 1996 |
|---|---|---|
| Total Revenues | $10,554,743 | $9,529,078 |
| Gross Profit | $8,095,377 | $7,255,208 |
| Gross Margin | 76.7% | 76.1% |
| Operating Income | $2,718,541 | $2,182,461 |
| Net Income | $1,749,407 | $1,497,879 |
| Diluted EPS | $0.13 | $0.11 |
| Cash and Equivalents (End of Period) | $3,998,896 | $4,018,619 |
| Net Cash from Operating Activities | $1,163,687 | $1,589,552 |
| Total Debt (Current + Long-term) | $6,363,235 | N/A |
| Current Ratio | 2.5:1 | N/A |
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 10.8% year-over-year. This was driven by a 10.0% rise in international sales (due to demand for foldable IOLs and new Glaucoma Wick/ICL products) and a 10.3% increase in U.S. sales (16.8% unit volume increase offset by a 5.9% price decrease).
- Profitability: Net income rose 16.8% to $1.75 million. Gross margin improved slightly to 76.7% due to operating efficiencies, despite a product mix shift toward higher-cost ELASTIMIDE IOLs.
- Expense Trends: Selling, general, and administrative (SG&A) expenses increased in absolute dollars but decreased as a percentage of revenue (from 53.2% to 50.9%) due to revenue absorption. R&D expenses increased 13.9% due to clinical studies and new product development.
- Liquidity: Cash and cash equivalents decreased by approximately $2.5 million from the beginning of the fiscal year, primarily due to debt repayments on Notes Payable and the Line of Credit.
Outlook, Risks, and Management Commentary
- Outlook: Management expects to continue being profitable. Future cash flow needs are anticipated to be met by operating cash flows or additional financing if required.
- Capital Allocation: The Company increased inventories, primarily internationally, to support new product rollouts. Investing activities consumed $1.03 million, largely for patents and equipment.
- Risks: International operations expose the Company to fluctuating exchange rates, foreign government regulations on fund transfers, export/import duties, and political instability.
- Accounting Update: The Company noted the issuance of SFAS 128 (Earnings per Share) but has not yet determined the effect of adoption on its EPS computation as it is effective for periods ending after December 15, 1997.
Investor Verification Checklist
- Verify the sustainability of the 16.8% unit volume increase in foldable IOLs against the 5.9% price decrease.
- Monitor the impact of foreign currency fluctuations on future earnings, given the significant portion of sales in Europe and other international markets.
- Assess the timeline and regulatory approval status for the new Glaucoma Wick and Implantable Contact Lens (ICL) products driving international growth.
- Review the Company's debt repayment schedule and the utilization of its Line of Credit to ensure liquidity remains sufficient for inventory build-up.
- Confirm the impact of the upcoming adoption of SFAS 128 on reported Earnings Per Share in future filings.